Nucleoside Metabolic Inhibitor [EPC]

156110 reported adverse events

Drugs of this class: FLUOROURACIL CAPECITABINE DECITABINE AZACITIDINE CLOFARABINE CYTARABINE TRIFLURIDINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE NELARABINE PENTOSTATIN TRIFLURIDINE AND TIPIRACIL

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

#	Side effect	Count
0	DIARRHOEA	15421
1	DEATH	12385
2	NAUSEA	10439
3	VOMITING	8598
4	FEBRILE NEUTROPENIA	8494
5	NEUTROPENIA	8228
6	DISEASE PROGRESSION	7524
7	FATIGUE	7329
8	PYREXIA	7309
9	THROMBOCYTOPENIA	5680

See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	131	0.8618
1	HUMAN BOCAVIRUS INFECTION	83	0.7094
2	ACUTE MYELOID LEUKAEMIA RECURRENT	397	0.4344
3	MYELODYSPLASTIC SYNDROME TRANSFORMATION	175	0.3631
4	CAECITIS	163	0.3622
5	PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	5190	0.3569
6	MYCOBACTERIUM CHELONAE INFECTION	147	0.3349
7	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY	82	0.3228
8	NEUTROPENIC COLITIS	310	0.3116
9	TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA	104	0.3104

See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]